Company news
Luye Pharma Group Ltd. (HKEX:2186) news
Luye Pharma Group Ltd. news releases on 6ix. Latest, Sep 29, 2026: Interim Report 2026
Press releases & updates
Interim Report 2026
September 29, 2026
Luye Pharma : Announces 2026 Interim Results
September 1, 2026
Luye Pharma : Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R ...
August 5, 2026
Luye Pharma : Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
June 16, 2026
Luye Pharma : Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
April 21, 2026
Luye Pharma : First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating ...
April 8, 2026
Luye Pharma : NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
January 8, 2026
Luye Pharma : Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
November 24, 2025
Luye Pharma : Announces 2025 Half-Year Results
August 29, 2025
Luye Pharma : All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
August 18, 2025
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
August 3, 2025
Luye Pharma : Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
April 10, 2025
Luye Pharma : Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of ...
April 6, 2025
Luye Pharma : Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
January 15, 2025
Luye Pharma : Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
November 11, 2024
Luye Pharma : Announces 2024 Half Year Results
August 29, 2024
Luye Pharma : mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
August 13, 2024
Luye Pharma : Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
August 5, 2024
Luye Pharma : Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating ...
July 28, 2024
Luye Pharma : Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
July 23, 2024
Luye Pharma : Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for ...
July 4, 2024
Luye Pharma : Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...
June 27, 2024
Luye Pharma : Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
June 19, 2024
Luye Pharma : Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
June 10, 2024
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong
December 12, 2023
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
October 31, 2023
Luye Pharma : The World’s Only Goserelin Microsphere Formulation (Baituowei) Approved in China for the New Indication of Breast Cancer
September 7, 2023
Luye Pharma : Announces 2023 Half Year Results
August 30, 2023
Luye Pharma : China’s NMPA Accepts and Grants Priority Review Designation to the New Drug Application for Luye Pharma’s Rotigotine Extended-Release ...
August 1, 2023
Luye Pharma : Patient Enrollment Completed for a Phase 2 Clinical Study of Luye Pharma’s Class 1 Analgesic Drug Candidate LY03014
July 6, 2023